BioSpace News Archive

Dover Motion, a designer and manufacturer of motion solutions for life sciences and diagnostics instruments, today announced the company’s new low-cost, high-performance 5 mm travel nanopositioning stage with built-in controller – the DOF-5 Dover Objective Focusing stage – was named a finalist in the 2019 PRISM Awards in the category of Optics & Optomechanics, as the product continues to gain recognition for its innovation by customers and influencers alike.

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805.

Yesterday, we learned of the passing of the Mental Health Commission of Canada’s (MHCC) Board Chair, the Hon. Michael Wilson.

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University announced its appointment of Angelika Fretzen, Ph.D., M.B.A., to the newly created position of Technology Translation Director.

VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the obtention of the European patent for TOTUM-63.

MediQuant®, the leading innovator and provider of enterprise active archiving solutions to hospitals and health systems, announced today the acquisition of DataEmerge, a leading data extraction service and long-time cooperative partner with MediQuant in supporting speed to value for clients.

Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe.

Emergency nurses need better education on the importance of assessing patients for firearms in the home and with how to inquire about the topic in a nonjudgmental, nonconfrontational manner, researchers with the Emergency Nurses Association concluded in a recent study.

Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, today named Mark Platt the organization’s Chief Executive Officer.

This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients